CAM
SCLN

Capstone Asset Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Capstone Asset Management’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$303K Sell
27,590
-750
-3% -$7.5K 0.01% 1253
2017
Q1 		$278K Sell
28,340
-1,750
-6% -$17.5K 0.01% 1345
2016
Q4 		$325K Buy
30,090
+15,130
+101% +$151K 0.01% 1265
2016
Q3 		$153K Sell
14,960
-110
-0.7% -$1.2K ﹤0.01% 1559
2016
Q2 		$197K Buy
+15,070
New +$197K 0.01% 1513

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capstone Asset Management's SCLN Position: Q2 2017 in Review

Capstone Asset Management reduced its Sciclone Pharmaceuticals Inc (SCLN) stake by 2.6% in Q2 2017, selling an estimated $7.5K and leaving 27,590 shares worth $303K. The position accounts for 0.01% of the portfolio, ranked #1253.

Capstone Asset Management first reported a position in SCLN in Q2 2016 and has held it in 5 quarters since. The position peaked at $325K in Q4 2016. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

  • Capstone Asset Management held 27,590 shares of Sciclone Pharmaceuticals Inc worth $303K as of Q2 2017.
  • Capstone Asset Management sold 750 Sciclone Pharmaceuticals Inc shares in Q2 2017, an estimated $7.5K.
  • Sciclone Pharmaceuticals Inc made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1253 holding.
  • Capstone Asset Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and has held it in 5 quarters since.
  • Capstone Asset Management's Sciclone Pharmaceuticals Inc position peaked at $325K in Q4 2016.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.